While there is no doubt about the potential of gene therapy in overcoming serious genetic disorders, it is important for investors to be aware of the fact that not all biotechs pursuing this form of treatment are created equal. According to this report from Research and Markets there have been hundreds of clinical trials to confirm the efficacy and safety of gene therapies since 2012 but only about 50 to 60 will receive commercial approval. One company that should however be on the radar of investors angling for a piece of this market should be Axovant Sciences (NASDAQ: AXGT) which . . .